SECURITIES PURCHASE AGREEMENT Dated June 24, 2014 by and between HEDGEPATH PHARMACEUTICALS, INC. and MAYNE PHARMA VENTURES PTY LTDSecurities Purchase Agreement • June 30th, 2014 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into this 24th day of June, 2014 (the “Signing Date”), by and between MAYNE PHARMA VENTURES PTY LTD, an Australian company ACN 168 896 357 (“Mayne Pharma”) and HEDGEPATH PHARMACEUTICALS, INC., a Delaware corporation (“HPPI”).
CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “***” EMPLOYMENT AGREEMENTEmployment Agreement • June 30th, 2014 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
THIS EMPLOYMENT AGREEMENT (the “Agreement”) dated as of June 24, 2014 (the “Effective Date”), is by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 324 South Hyde Park Avenue, Tampa FL 33606 (the “Company”) and Nicholas J. Virca (the “Executive”).
DEBT FORGIVENESS AGREEMENTDebt Forgiveness Agreement • June 30th, 2014 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
THIS DEBT FORGIVENESS AGREEMENT (this “Agreement”) is made and entered into and effective as of this 24th day of June, 2014 by and between HEDGEPATH PHARMACEUTICALS, INC., a Delaware corporation (“HPPI”), and HEDGEPATH, LLC a Delaware limited liability company (“HP LLC”).
EXECUTIVE CHAIRMAN AGREEMENTExecutive Chairman Agreement • June 30th, 2014 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Florida
THIS EXECUTIVE CHAIRMAN AGREEMENT (the “Agreement”) is made as of the 24th day of June, 2014 (the “Effective Date”) and is by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Frank E. O’Donnell. Jr., M.D. (the “Executive Chairman”).
Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with “***” HEDGEPATH PHARMACEUTICALS, INC. EQUITY HOLDERS...Equity Holders Agreement • June 30th, 2014 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
This EQUITY HOLDERS AGREEMENT (this “Agreement”) is made and entered into as of the 24th day of June, 2014 (the “Effective Date”) by and among:
STOCK PURCHASE AGREEMENTStock Purchase Agreement • June 30th, 2014 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of June 24, 2014, is made and entered into by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Hedgepath, LLC, a Florida limited liability company (the “Purchaser”).
PROMISSORY NOTEPurchase Agreement • June 30th, 2014 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
This PROMISSORY NOTE (this “Note”) is being issued and delivered pursuant to the terms of that certain Stock Purchase Agreement, dated June 24, 2014 (the “Purchase Agreement”), by and between the Maker (as defined below) and the Payee (as defined below). All capitalized terms used but not defined herein shall have the meanings ascribed to them in the Purchase Agreement.
Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with “***”HedgePath Pharmaceuticals, Inc. • June 30th, 2014 • Services-commercial physical & biological research • Delaware
